3rd Quarter - Report

EXECUTIVE STRATEGIES, LTD. CO. for SENTINEL API GROUP, INC.

Firm
Client
Income
$20,000
Expenses
—

What was lobbied

One issue area, each in the filer's own words, with who lobbied on it and where.

Manufacturing MAN

Legislation, policies, appropriations, and regulatory relief to support the development, construction, and operation of new U.S.-based active pharmaceutical ingredient (API) manufacturing facilities; initiatives to strengthen domestic API supply chains and reduce reliance on foreign-sourced APIs; FDA regulatory streamlining and expedited review for new API manufacturing plants; federal grant, tax incentive, and contracting mechanisms to increase private investment in domestic API production; implementation of Executive Order(s) or federal policy aimed at boosting U.S.-based pharmaceutical manufacturing; relevant provisions of H.R. 1405 (Enhancing Domestic Drug Manufacturing Act), S. 257 (Promoting Resilient Supply Chains Act of 2025), the RAPID Reserve Act, and other pending bills and actions to advance U.S. pharmaceutical supply chain resilience and capacity.

LobbyistCovered position, as disclosed
TYLER BEAVER —

Contacted: Health & Human Services, Dept of (HHS)

Bills named: S. 257 (119th), H.R. 1405 (119th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.